Blood based monitoring for all solid organ tumours

cancertrack is a blood-based analysis that detects cancer related biomarkers with high precision, specificity and reliability. cancertrack enables continuous monitoring of the cancer in order to detect relapses or changes in the tumour characteristics at an early stage.

Features of cancertrack

  • Detection of circulating tumour DNA (ctDNA), which is released into the patient's blood by cancer cells
  • Upon request: in combination with circulating tumour cells (CTCs)
  • Real-time adaption of the medication based on the test results
  • Detection of tumour activity at an early stage
  • Monitoring of non-visible metastases and tumours
  • Limits of detection: 0.1% (Minor Allele Frequency)
  • Secure, simple and cost-effective

cancertrack is suitable for

<p>... every patient who is under treatment for cancer.</p>

... every patient who is under treatment for cancer.

<p>... every person who has been diagnosed with cancer, as a supplement to conventional biopsy and imaging.</p>

... every person who has been diagnosed with cancer, as a supplement to conventional biopsy and imaging.

<p>... every patient who is in remission / a cancer survivor and needs monitoring.</p>

... every patient who is in remission / a cancer survivor and needs monitoring.

Monitoring cancer

At best, the treatment is always one step ahead of the cancer disease. cancertrack ensures real-time monitoring to detect genetic changes in the tumour. Clinically relevant mutations can be identified and the treatment can be customised accordingly.

What does cancertrack reveal?

  • ctDNA & CTC*

    Information on cancer activity

  • ctDNA

    Molecular dynamics in real-time

  • ctDNA & CTC*

    Indications for therapy success

  • ctDNA

    Quantitative markers for longitudinal monitoring

Comparison chart cancertrack

cancertrack is primarily used to monitor solid tumours - both during and after therapy. The focus is on the analysis of circulating tumour DNA (ctDNA), which provides information on disease activity. In addition, circulating tumour cells can provide information on the course of the disease and the effectiveness of the therapy as a further biomarker. In combination with other methods, such as transcriptome analysis, cancertrack can also contribute to therapy planning under certain conditions. cancertrack MRD combines ctDNA analysis with additional tissue analysis and digital droplet PCR (ddPCR). The increased sensitivity due to ddPCR enables the test to provide a more precise assessment of the necessity of further therapies after surgery, for example.

View comparison (PDF)

FAQ

Why is early detection of molecular dynamics of cancer critical?

The molecular evolution of the tumour, including tumour size and molecular diversification, is a continuous process that can progress at high speed. Therefore, early detection of recurrence or drug resistance is essential to keep the cancer under control.

How frequently is it necessary to perform the test?

cancertrack should ideally be performed at every important milestone in the fight against cancer and especially when the tumour has disappeared from conventional imaging / patient is under follow-up for recurrence monitoring, usally every 3 - 12 months.

Sample requirement and Turn Around Time (TAT)
  • 40 ml blood in DCGL and EDTA tubes
  • 8 – 10 working days from receipt of the sample in the laboratory